Table 1.
List of lncRNAs associated with platinum-resistance in ovarian cancer.
| lncRNA | Category | Expression in OC tissue* | Expression in platinum-resistant cell lines** | Mechanisms of resistance*** | References |
|---|---|---|---|---|---|
| HOTAIR | Antisense | ↑ (cisplatin resistance or treated with carboplatin) | ↑ (cisplatin/carboplatin) | ↑ HOXA7 | (107–110) |
| MALAT1 | Intergenic | ↑ | ↑ (cisplatin) | ↑ Notch1 → ↑ abcc1 | (111, 112) |
| H19 | Intergenic | ↑ (recurrent disease) | ↑ (cisplatin) | ↑ GSH pathway | (113) |
| ZFAS1 | Antisense | ↑ (platinum resistance) | ↑ (cisplatin) | ↓ miR-150-5p → ↑ SP1 | (80, 114) |
| UCA1 | Intergenic | ↑ (cisplatin resistance) | ↑ (cisplatin) | ↑ SRPK1 ↓ miR-143 → ↑ FOSL2 | (115–117) |
| PANDAR | Antisense | ↑ (disease recurrence + wt-p53) | ↑ (cisplatin) | ↓ NF-YA ↑ SFRS2 - ↓ p53 | (118) |
| PVT1 | Intergenic circRNA | ↑ (cisplatin resistance) | ↑ (cisplatin) | ↑ c-MYC | (119) |
| ZBED3-AS1 | Antisense | ↑ (platinum resistance) | ↑ (cisplatin/carboplatin) | N/A | (120) |
| F11-AS1 | Antisense | ↓ (platinum resistance) | ↓ (cisplatin/carboplatin) | N/A | (120) |
| GAS5 | Intergenic | ↓ (platinum resistance) | ↓ (cisplatin/carboplatin) | N/A | (120) |
| BC200 | Intergenic | ↓ | ↓ (carboplatin) | N/A | (121) |
| LINC00312 | Intergenic | ↓ (cisplatin+paclitaxel resistance) | ↓ (cisplatin) | ↑ Bcl-2/Caspase-3 pathway | (122) |
| BX641110 | N/A | ↑ (cisplatin) | N/A | (123) | |
| CRNDE | Intergenic | N/A | ↑ (cisplatin) | N/A | (123) |
| HOXC-AS3 | Antisense | N/A | ↑ (cisplatin) | N/A | (123) |
| RP11-384P7.7 | Intergenic | N/A | ↑ (cisplatin) | N/A | (123) |
| PLAC2 | Intronic | N/A | ↑ (cisplatin) | N/A | (123) |
| RP11-6N17 | Intergenic | N/A | ↑ (cisplatin) | N/A | (123) |
| RP11-65J3.1-002 | Intergenic | N/A | ↓ (cisplatin) | N/A | (123) |
| AC141928.1 | Intergenic | N/A | ↓ (cisplatin) | N/A | (123) |
| GS1-600G8.5 | Intergenic | N/A | ↓ (cisplatin) | N/A | (123) |
| SNHG15 | Intergenic | ↑ | ↑ (cisplatin) | N/A | (124) |
| EBIC | Processed pseudogene | ↑ | ↑ (cisplatin) | ↑ Wnt/β-catenin pathway | (125) |
The order of the lncRNAs corresponds to the appearance of the individual descriptions in the manuscript. Only the first 7 lncRNAs are described in detail in the manuscript, and are selected based on substantiating evidence in the literature.
The expression of the lncRNAs in OC tissue is indicated by arrows, ↑ for higher and ↓ for lower expression in platinum-resistant patients (patient characteristics indicated in parenthesis), compared to expression in platinum-sensitive patients. If no patient characteristics are indicated, the expression was determined in ovarian cancer tissue from patients with unspecified sensitivity to platinum drugs and normalized to adjacent or normal ovarian tissue.
The expression in resistant OC cell lines is indicated by arrows; ↑ for higher and ↓ for lower expression in platinum-resistant, compared to expression in platinum-sensitive cell lines. The drug the cell lines are resistant to is indicated in parenthesis.
The effect of lncRNAs on associated pathways, miRNAs, genes or transcription factors involved in resistance mechanisms are indicated by arrows: ↑ induction and ↓ repression.
N/A, information not available.